



METHODOLOGY CONTACT US

VENABLE LLP

BIOLOGICSHQ SEARCH NEWS STATISTICS BIOLOGICSHQ TEAM RESOURCES SUBSCRIBE

Statistics at a Glance



Patents Subject to Biosimilar-Related IPRs and Litigations

Patents Subject to IPRs and Litigations
76.6%



Patents Subject to IPRs Only
23.4%



VENABLE LLP

As of Jun. 15, 2025

© Venable LLP 2025. All Rights Reserved.

Biosimilar-Related Litigations include litigations relating to biosimilar/follow-on products and include insulin. Litigations between biosimilar applicants/manufacturers and reference product sponsors as well as litigations between two biosimilar applicants/manufacturers are included. Litigations relating to disputes between two reference product sponsors, or non-practicing entities/universities and reference product sponsors are not included. Litigations related solely to manufacturing patents that may be relevant to multiple products (for example, U.S. Patent Nos. 6,331,415, 7,923,221, and 4,816,567 ("Cabily Patents")) also are not included.

Biosimilar-Related IPR Petitions include IPR petitions relating to biosimilar/follow-on products and include insulin. IPR petitions relating to disputes between two reference product sponsors, or non-practicing entities/universities and reference product sponsors are not included. IPR petitions relating to manufacturing patents that may be relevant to multiple products (for example, U.S. Patent Nos. 6,331,415, 7,923,221, and 4,816,567 ("Cabily Patents")) also are not included.

BiologicsHQ and materials published on BiologicsHQ are published for informational purposes only. Neither the information nor any opinion expressed on BiologicsHQ constitute legal advice, create an attorney-client relationship, or constitute a solicitation for business.

SHARE



ATTORNEY ADVERTISING

© / TM / © Venable LLP 2025. All Rights Reserved.

Related Websites

VENABLE.COM → DISCLAIMER →